Immortalized Corneal Stem Cell Exosomes for Scar Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The severe shortage of transplantable cornea tissues for treating corneal scarring and the limitations of conventional therapies, including the undefined components of exosomes, hinder effective treatment options for corneal blindness.
Innovation Solution
Development of exosomes derived from immortalized corneal stromal stem cells, which produce a consistent supply of defined polynucleotides and proteins to reduce scarring by delivering therapeutic agents directly to corneal tissues, avoiding the need for surgical intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corneal transplantation is performed to treat corneal scarring, then vision restoration is achieved, but the severe shortage of transplantable cornea tissues limits availability to less than 5% of affected people
Solution Approach 1:
The invention extracts and utilizes specific functional components (exosomes containing polynucleotides and proteins) from corneal stromal stem cells, rather than transplanting entire corneal tissues. This extraction approach enables production of therapeutic agents without requiring scarce donor corneas, thereby resolving the contradiction between treatment efficacy and tissue availability
Solution Approach 2:
The invention creates copies of therapeutic molecules (polynucleotides and proteins) that are naturally present in corneal stromal stem cell exosomes. By identifying and replicating these specific molecular components, the invention enables mass production of therapeutic agents that mimic the healing effects of natural corneal tissues without requiring actual tissue transplants
2Adaptability or versatility
If conventional exosome therapy is used for corneal scarring, then treatment potential is achieved, but the undefined components of exosomes create challenges in therapy standardization
Solution Approach 1:
The invention focuses on specific local components within exosomes (particular polynucleotides and proteins) rather than treating exosomes as undifferentiated entities. By identifying and isolating specific therapeutic molecules with defined sequences and functions, the invention enables precise manufacturing and standardization while retaining the therapeutic versatility of exosome-based therapy
Solution Approach 2:
The invention segments the complex exosome structure into identifiable and isolatable components (specific polynucleotides and proteins). This segmentation allows for separate characterization, purification, and standardization of individual therapeutic molecules, thereby resolving the manufacturing precision challenges while preserving the overall therapeutic adaptability
3Reliability
If primary stem cells are used to obtain exosomes, then therapeutic effectiveness is maintained, but the limited availability and lifespan of primary cells restricts scalable production
Solution Approach 1:
The invention identifies and replicates the specific polynucleotide and protein profiles found in primary stem cell-derived exosomes. By copying these molecular signatures through controlled expression systems, the invention enables scalable production of therapeutically equivalent exosomes without being constrained by the limited availability and lifespan of primary stem cells
Data Source
Figure 1A~1B
Figure 2
Figure 3A~3F
AI summary
Corneal stromal scars are the leading cause of corneal blindness. The present invention relates to methods and compositions useful in therapies for this pathological condition. The invention provides corneal stromal stem cells and certain other stem cells and as well as exosome polynucleotides produced by such cells, and methods for making and using these cells and compositions. The invention is based upon the discovery that exosomes and their associate active components obtained from these cells comprise agents having the same capacity as corneal stromal stem cells to reduce scarring and prevent scar formation in patients having corneal damage.